Pluristem Therapeutics Inc
) recently announced that it will release the results of its
phase I/II clinical trial, evaluating the safety and efficacy of
PLacental Expanded (PLX-PAD) cells for the treatment of muscle
injury, on Jan 21, 2014.
Pluristem develops and manufactures cell therapy products in
collaboration with companies like
) or through research and clinical institutions.
The cells from placenta are derived using the company's
proprietary PluriX therapy and are known as PLacental eXpanded
cells. Pluristem's first candidate in development, PLX-PAD, is
intended to treat peripheral artery disease (PAD).
We note that Pluristem intends to develop and produce cell
therapy products for the treatment of multiple disorders using
several methods of administration.
The phase I/II study comprised three treatment groups - two
PLX-PAD groups of different doses and one placebo group. The
study was initiated in Apr 2013. The primary endpoints of the
trial were safety and the maximal contraction force of the
gluteal muscle at six months post-surgery while the secondary
endpoints included an analysis of the macrostructure and
microstructure of the gluteal muscle using magnetic resonance
imaging (MRI) and biopsy.
A positive outcome from this study will enable Pluristem to
further evaluate the potential of PLX-PAD cells for this
indication along with other potential surgical orthopedic
injuries and non-surgical sports related injuries. We expect
investor focus on results from the trial.
Pluristem currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same sector include
Lannett Company, Inc
) with a Zacks Rank #1 (Strong Buy).
FOREST LABS A (FRX): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
PLURISTEM THERA (PSTI): Free Stock Analysis
UTD THERAPEUTIC (UTHR): Free Stock Analysis
To read this article on Zacks.com click here.